<DOC>
<DOCNO>EP-0617036</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Novel 2-thiosubstituted carbapenems.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31397	A61K31397	A61K3140	A61K3140	A61K314015	A61K314015	A61K31403	A61K31403	A61K3142	A61K3142	A61K31425	A61K31425	A61K3144	A61K3144	A61K31495	A61K31495	A61K31535	A61K31535	A61P3100	A61P3100	A61P3104	C07D30700	C07D30718	C07D33300	C07D33334	C07D33348	C07D47700	C07D47700	C07D47704	C07D47706	C07D47712	C07D47714	C07D47720	C07F900	C07F96561	C07H1100	C07H1100	C07H1900	C07H1901	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07F	C07F	C07H	C07H	C07H	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P31	A61P31	A61P31	C07D307	C07D307	C07D333	C07D333	C07D333	C07D477	C07D477	C07D477	C07D477	C07D477	C07D477	C07D477	C07F9	C07F9	C07H11	C07H11	C07H19	C07H19	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Carbapenem antibiotic compounds of the general
formula:



wherein the moiety


is a 4, 5 or 6 membered mono, di- or tri- substituted
oxygen or sulfur containing ring; wherein Z is oxygen,

sulfur, sulfoxide and sulfone, pharmaceutical
compositions thereof useful for the treatment of

bacterial infections, processes for preparing the
compounds and new intermediates useful in the process.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
AMERICAN CYANAMID CO
</APPLICANT-NAME>
<APPLICANT-NAME>
AMERICAN CYANAMID COMPANY
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BITHA PANAYOTA
</INVENTOR-NAME>
<INVENTOR-NAME>
BUSH KAREN
</INVENTOR-NAME>
<INVENTOR-NAME>
LIN YANG-I
</INVENTOR-NAME>
<INVENTOR-NAME>
SAKYA SUBAS
</INVENTOR-NAME>
<INVENTOR-NAME>
STROHMEYER TIMOTHY W
</INVENTOR-NAME>
<INVENTOR-NAME>
BITHA, PANAYOTA
</INVENTOR-NAME>
<INVENTOR-NAME>
BUSH, KAREN
</INVENTOR-NAME>
<INVENTOR-NAME>
LIN, YANG-I
</INVENTOR-NAME>
<INVENTOR-NAME>
SAKYA, SUBAS
</INVENTOR-NAME>
<INVENTOR-NAME>
STROHMEYER, TIMOTHY W.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to novel carbapenem 
antibiotics and non-toxic pharmaceutically acceptable 
salts thereof, which have antimicrobial activity. 
Therefore, the present carbapenem antibiotics and 
pharmaceutical compositions thereof are useful in the 
treatment of bacterial infections in humans and animal, 
either alone or in combination with other antibiotics. 
The present invention also provides processes for the 
preparation of the carbapenem antibiotics and of certain 
novel intermediates. This invention is concerned with novel carbapenems, 
represented by formula I, which have antibacterial 
activity; with methods of treating infectious 
disease in humans and other animals when administering 
these new compounds; with pharmaceutical preparations 
containing these compounds; with novel intermediate 
compounds and stereoselective processes for the production 
of compounds of formula IV; and with the production 
of compounds of formulae I. 
wherein the moiety 
is a 4,5 or 6 membered mono-, di- or tri-substituted 
oxygen or sulfur containing ring. For example, the moiety 
may be a 5 membered ring of the formula 
In such an instance, the following isomers are 
included: 
and the stereochemical assignment of each residue 
and ―(CH₂)nR₂ 
on the 4, 5 or 6-membered ring (containing the Z 
substituent) can be either R or S. As stated, the invention relates to compounds of 
Formula I: 
wherein the moiety: 
represents a 4,5 or 6 membered mono, di-or 
tri-substituted ring and 
(A) Z is selected from oxygen, sulfur, sulfoxide and 
sulfone; when Z is sulfoxide, the relative stereochemistry 
between the substituent and the 
sulfoxide can be cis or trans; (B) Ro is hydrogen, (C₁-C₂)alkyl, CH₂OR₄, CH₂NHR₅, 
CH(OR₄)CH₃, CHFCH₃ or CH(NHR₅)CH₃; wherein 
(i) R₄ is selected from hydrogen, and moieties of 
the formulae:  (ii) R₅ is selected from hydrogen, and moieties of 
the formulae: 
(iii) R₆ is selected from a straight, branched or 
substituted (C₁-C₁₈)alkyl, (C₂-C₁₈) alkenyl, 
unsubstituted or substituted (C₃-C₇)monocyclo(C₁-C₁₀)alkyl, 
unsubstituted or 
substituted (C₅-C₁₀)bicyclo(C₁-C₁₀)alkyl, 
aryl or substituted aryl, heteroaryl or 
substituted heteroaryl, heterocyclyl or 
substituted heterocyclyl; the substitution 
for the alkyl, monocycloalkyl and bicycloalkyl 
moieties are selected from trifluoromethyl, 
pentafluoroethyl, amino, mono(C₁-C₆)-alkylamino, 
di(C₁-C₆)alkylamino, hydroxy, 
(C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, carboxy, 
(C₂-C₁₀)carboalkoxy, cyano and (C₁-C₁₀)carboxamido; 
the substitution for the
</DESCRIPTION>
<CLAIMS>
A compound of formula I: 
 

wherein the moiety 
 

represents a 4,5 or 6 membered mono-, di- or tri- 
substituted ring wherein: 


(A) Z is selected from oxygen, sulfur, sulfoxide and 
sulfone; 
(B) Ro is hydrogen, (C₁-C₂)alkyl, CH₂OR₄, CH₂NHR₅, 
CH(OR₄)CH₃, CHFCH₃ or CH(NHR₅)CH₃; wherein 


(i) R₄ is selected from hydrogen, and moieties of 
the formulae: 


(ii) R₅ is selected from hydrogen, and moieties of 
the formulae: 
(iii) R₆ is selected from a straight, branched or 
substituted (C₁-C₁₈)alkyl, (C₂-C₁₈)alkenyl, 

unsubstituted or substituted 
(C₃-C₇)monocyclo(C₁-C₁₀)alkyl, unsubstituted 

or substituted (C₅-C₁₀)bicyclo(C₁-C₁₀)alkyl, 
aryl or substituted aryl, heteroaryl or substituted 

heteroaryl, heterocyclyl or substituted 
heterocyclyl; wherein the heterocyclyl 

moiety is a monocyclic or bicyclic group 
having 1-10 carbon atoms and 1-4 hetero atoms 

selected from oxygen, nitrogen or sulfur 
atoms and each ring of the heterocycle is 

comprised of 4 to 7 atoms, the heteroaryl 
group is an aromatic monocyclic or bicyclic 

heterocyclic group of 5-12 atoms wherein the 
heteroatom or heteroatoms are selected from 

1-4 oxygen, nitrogen or sulfur atoms; the 
substitution for the alkyl, monocycloalkyl 

and bicycloalkyl moieties are selected from 
trifluoromethyl, pentafluoroethyl, amino, 

mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 
hydroxy, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, 

carboxy, (C₂-C₁₀)carboalkoxy, cyano and 
(C₁-C₁₀)carboxamido; the substitution for the 

aryl, heteroaryl and heterocyclyl moieties is 
selected from (C₁-C₆)alkyl, (C₁-C₆)mono-, di- 

or polyfluoroalkyl, hydroxy, (C₁-C₆)alkoxy, 
(C₃-C₈)cycloalkoxy, amino, 

 
mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 

carboxy, (C₂-C₁₀)carboalkoxy, cyano and 
(C₁-C₁₀)carboxamido; 
(C) R₁ is straight or branched (C₁-C₈)alkyl, straight 
or branched (C₂-C₈)alkenyl, (C₃-C₈)cycloalkyl, or 

(CH₂)n,R; wherein 
n' is an integer of from 1-6; R is selected from 

CF₃, C₂F₅, fluorine, chlorine, bromine, hydroxy, 
alkoxy, nitrile, azido, a quaternary ammonio 

group, amidino, formamidino, guanidino and NR'R''; 
wherein 


(i) R' and R'' are independently selected from 
hydrogen, straight or branched (C₁-C₆)alkyl, 

straight or branched (C₁-C₆)alkoxy, 
2-hydroxyethyl, 2-azidoethyl and 

2-aminoethyl; 
(ii) and when R' is hydrogen or straight or 
branched (C₁-C₆)alkyl, R'' may also be 

selected from amino, hydroxy, 
mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 

acyl, benzoyl, dihydroxybenzoyl, an acyl 
residue of an amino acid or peptide, and 

straight or branched substituted (C₁-C₆)alkyl 
wherein said alkyl substituent is selected 

from hydroxy, (C₁-C₆)alkoxy, azido, amino, 
mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 

guanidino, nitrile, carboxy, formimidoyl and 
phenyl; or 
(iii) R' and R'' taken together with the associated 
nitrogen is an unsubstituted or substituted 

monocyclic or bicyclic heterocyclic ring 
having up to four (4) heteroatoms in each 

ring independently selected from oxygen, 
nitrogen and sulfur, wherein said 

substituent is selected from straight or 
branched (C₁-C₆)alkyl, straight or branched 

(C₁-C₆)alkoxy, (C₃-C₈)cycloalkyl, 
 

(C₃-C₈)cycloalkoxy, trifluoromethyl, hydroxy, 

halogen (selected from bromine, chlorine, 
fluorine and iodine), amino, nitrile, 

carboxy, carbamido, carbamoyl, straight or 
branched mono(C₁-C₆)alkylamino, straight or 

branched di(C₁-C₆)alkylamino, and 
amino(C₁-C₆)alkyl; 
 
and wherein the substituent or substituents on the 

 
moiety are independently selected from moieties of the 

formula -(CH₂)nR₂ wherein 
(D) n is an integer from 0-4; 
(E) R₂ is: 

(i) methyl, fluorine, chlorine, bromine, iodine, 
-OCOCH₃, -OCOCF₃, -OSO₂CH₃, -OSO₂Ph, azido, 
(ii) a moiety of the formula: 
-S(O)n''Ra 

wherein n'' is an integer from 0-2; 
and Ra is 


(a) hydrogen or an 
(b) organic group bonded via a carbon atom 
selected from substituted or 

unsubstituted (C₁-C₆)alkyl, substituted 
or unsubstituted (C₃-C₇)cycloalkyl, substituted 

or unsubstituted 
(C₂-C₆)alkenyl, substituted or 

unsubstituted (C₂-C₆)alkynyl, substituted 
or unsubstituted aryl, substituted 

or unsubstituted heteroaryl, substituted 
or unsubstituted aryl(C₁-C₆)alkyl, substituted 

or unsubstituted 
heteroaryl(C₁-C₆)alkyl, substituted or 

unsubstituted (C₁-C₆)alkanoyl, substituted 
or unsubstituted arylcarbonyl, 

 
substituted or unsubstituted heteroarylcarbonyl, 

substituted or unsubstituted 
heterocyclyl, substituted or 

unsubstituted heterocyclyl(C₁-C₆)alkyl, 
substituted or unsubstituted heterocyclyl(C₁-C₆)thioalkyl; 

said substitution 
is selected from (C₁-C₆)alkyl, 

hydroxy (C₁-C₆)alkoxy, phenyl, heterocyclyl, 
amino, amidino, guanidino, 

carboxamido, carbamoyl 
(C₁-C₆)alkanoylamino, mono- and 

di(C₁-C₆)alkylamino and quaternary 
ammonio; 
(iii) or R₂ is selected from hydroxy, -ORa, 
-OC(O)Ra, -OC(O)ORa, -OC(O)NRaRa or 

 
wherein Ra is independently selected and is 

as hereinabove defined or 
 

wherein R₁₃ is a moiety selected from those 
of the formulae:  

wherein B⁻ is a physiologically acceptable 
anion; 
(iv) or R₂ is an organic residue bonded via a 
nitrogen atom, selected from: 


(a) NO, NO₂, NO₃, NC, NCO, NHCN, and NRhRJ 
wherein Rh and RJ are independently 

selected from hydrogen; amino, substituted 
amino, substituted or unsubstituted 

(C₁-C₈)alkyl and 
(C₃-C₈)cycloalkyl(C₁-C₈)alkyl, aryl, 

aralkyl, heterocyclyl, heterocyclyl-(C₁-C₄)alkyl, 
heteroaryl and heteroaryl-(C₁-C₄)alkyl 

wherein the heteroaryl and 
heterocyclyl groups are as hereinbefore 

described and a cyclic group wherein Rh 
and RJ taken together with the associated 

nitrogen is an unsubstituted or 
substituted mono- or bicyclic heterocyclic 

ring having up to four (4) 
heteroatoms in each ring independently 

selected from oxygen, nitrogen and 
sulfur wherein the substituents in the 

above mentioned substituted alkyl, amino 
and heterocyclic group consist of amino, 

mono-, di- and tri(C₁-C₆)alkylamino, 
hydroxyl, oxo, carboxyl, alkoxyl, 

chloro, fluoro, bromo, nitro, -SO₂NH₂, 
phenyl, benzyl, acyloxy, alkoxylcarbonyloxy, 

cyclo- alkoxycarbonyloxy and 
carboxamido; 
(b) a hydroxylamino, hydrazinyl, iminyl and 
hydroxamic acid derivative of the 

formulae: 
―N(Rh)ORJ,―N(Rh)NRhRJ,  

respectively: wherein Rh and RJ are as 
hereinabove defined; 
(c) moieties of the formulae: 
 

   and 
 

wherein Rh and RJ are as hereinabove 
defined; 
(d) acylamino moieties of the formulae: 
 

wherein Rh and RJ are as hereinabove 
defined; 
(e) moieties represented by the formulae: 

 

wherein Rh and RJ are as hereinabove 
defined and RP is selected from oxygen 

and sulfur; 
(f) moieties of the formula: 
 

wherein Rk represents hydrogen, 
(C₁-C₃) alkyl* (C₂-C₆)alkenyl*, 

(C₂-C₆)alkynyl*, heterocyclyl* and 
heteroaryl* wherein the heteroaryl and 

heterocyclyl groups are as hereinbefore 
described, wherein the aforesaid alkyl, 

alkenyl, alkynyl, heterocyclyl and 
heretoaryl group is optionally substituted 

by a substituent as described 
hereinabove for Rh and RJ; 
(g) moieties of the formula: 
RaS(O)n''NH- 

wherein n'' and Ra are as hereinabove 
defined; 
(h) moieties represented by the formulae: 
 

wherein Rh and RJ are as hereinabove 
defined; 
(i) an amino moiety containing an acyl 
residue of an amino acid or peptide 

represented by the formula:  
wherein Rh is as hereinabove defined; Rm 

is hydrogen or an acyl residue of an 
amino acid or peptide; and Rt is hydrogen, 

benzyl, straight or branched 
(C₁-C₆)alkyl optionally substituted with 

halo, hydroxy, amino, guanidinyl, 
carboxy, phenyl, aminocarbonyl, 

alkylthio, hydroxyphenyl or 
heterocyclyl; 
(j) an acyclic quaternary ammonio moiety of 
the formula: 

B⁻ -N⁺R₇R₈R₉ 
wherein R₇, R₈ and R₉ are the same or 

different and are selected from hydrogen, 
a straight or branched 

(C₁-C₆)alkyl, (C₂-C₆)alkenyl and substituted 
(C₁-C₆)alkyl, wherein the substitution 

is selected from hydroxy, 
(C₁-C₆)alkoxy, azido, amino, 

(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 
guanidino, nitrile, carboxy, formimidoyl 

and phenyl; alternatively, R₇ and R₈ 
taken together are -(CH₂)₂X(CH₂)₂-, 

wherein X is (CH₂)w (w is an integer 
from 0 to 2), oxygen, sulfur, NH, NRh, 

NOH and NORh and B⁻ is a physiologically 
acceptable anion, 
(k) a quaternized heteroaryl wherein the 
heteroaryl moiety must contain at least 

one positively charged nitrogen atom in 
association with a physiologically 

 
acceptable anion, wherein the 

quaternized heteroaryl is optionally 
substituted by Ra as hereinabove 

defined; and 
(v) or R₂ is a moiety bonded via a carbon atom 
selected from the following groups: 


(a) a nitrile moiety, acetylenic moiety or 
a moiety of the formulae: 

-C≡ C - Ra 
wherein Ra is as hereinabove defined; 
(b) a moiety selected from the formulae:  
wherein Ra, Rh and RJ are as hereinabove 

defined; and 
(c) a moiety selected from -CHF₂, CF₃, 
-CF₂CF₃, -CH(OCH₃)₂, -CHCl₂, and 

-CHRhRJ; 
(F) R₃ is selected from hydrogen; a straight or 
branched (C₁-C₄)alkyl group; a (C₁-C₄)alkoxymethyl 

group; a straight or branched 1-(C₁-C₅)aliphatic 
acyloxy-ethyl or methyl group; a straight, 

branched or cyclic 1-(C₁-C₆)alkoxycarbonyloxyethyl 
or methyl group; a phthalidyl group; and 

water soluble cations selected from the group 
consisting of lithium, sodium, potassium, ammonium 

and tetra(C₁-C₄)alkyl ammonium and the 
pharmaceutically acceptable salts thereof. 
A compound according to Claim 1, 
wherein: 


(A) Z is selected from oxygen; 
(B) Ro is -CH(OR₄)CH₃; wherein 
   R₄ is selected from hydrogen and moieties of the 

formula:  
wherein R₆ is selected from a straight, branched 

or substituted (C₁-C₁₈)alkyl, (C₂-C₁₈)alkenyl, 
unsubstituted or substituted 

(C₃-C₇)monocyclo(C₁-C₁₀)alkyl, unsubstituted or 
substituted (C₅-C₁₀)bicyclo(C₁-C₁₀)alkyl, aryl or 

substituted aryl, heteroaryl or substituted 
heteroaryl, heterocyclyl or substituted 

heterocyclyl; wherein the substitution for the 
aforesaid alkyl, monocycloalkyl and bicycloalkyl 

group is selected from trifluoromethyl, 
pentafluoroethyl, amino, mono(C₁-C₆)alkylamino, 

di(C₁-C₆)alkylamino, hydroxy, (C₁-C₆)alkoxy, 
(C₃-C₈)cycloalkoxy, carboxy, (C₂-C₁₀)carboalkoxy, 

cyano, and (C₁-C₁₀)carboxamido; the substitution 
for the aforesaid aryl, heteroaryl an
d 
heterocyclyl group is selected from (C₁-C₆)alkyl, 

(C₁-C₆)mono-, di- or polyfluoroalkyl, hydroxy, 
(C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, amino, 

mono(C₁-C₆)alkylamino,di(C₁-C₆)alkylamino, 
carboxy, (C₂-C₁₀)carboalkoxy, cyano and 

(C₁-C₁₀)carboxamido; 
(C) R₁ is straight or branched (C₁-C₄)alkyl, straight 
or branched (C₂-C₄)alkenyl, (C₃-C₆)cycloalkyl, or 

(CH₂)n,R; wherein 
n' is an integer of from 1-4; R is selected from 

CF₃, C₂F₅, fluorine, chlorine, bromine, hydroxy, 
alkoxy, nitrile, azido, a quaternary ammonio 

group, amidino, formamidino, guanidino and NR'R''; 
wherein: 
(i) R' and R'' are independently selected from 
hydrogen, straight or branched (C₁-C₄)alkyl, 

and straight or branched (C₁-C₄)alkoxy; 
and 
(ii) when R' is hydrogen or straight or branched 
(C₁-C₄)alkyl, R'' may also be selected from 

amino, hydroxy, mono(C₁-C₄)alkylamino, 
di(C₁-C₄)alkylamino, acyl, benzoyl, 

dihydroxybenzoyl, and an acyl residue of an 
amino acid or peptide; 

or 
(iii) R' and R'' taken together with the associated 
nitrogen is an unsubstituted or substituted 

monocyclic or bicyclic heterocyclic ring 
having up to four (4) heteroatoms in each 

ring independently selected from oxygen, 
nitrogen and sulfur, wherein said 

substituent is selected from straight or 
branched (C₁-C₄)alkyl, straight or branched 

(C₁-C₄)alkoxy, (C₃-C₆)cycloalkyl, 
(C₃-C₆)cycloalkoxy, trifluoromethyl, hydroxy, 

halogen (selected from bromine, chlorine, 
fluorine and iodine), amino, nitrile, 

carboxy, carbamido, carbamoyl, straight or 
branched mono(C₁-C₄)alkylamino, straight or 

branched di(C₁-C₄)alkylamino, and 
amino(C₁-C₄)alkyl; 
(D) n is an integer from 0-4; 
(E) R₂ is 

(i) methyl, fluorine, chlorine, bromine, iodine, 
-OCOCH₃, -OCOCF₃, -OSO₂CH₃, -OSO₂Ph, azido, 
(ii) a moiety of the formula: 
-S(O)n''Ra 

wherein n''is an integer from 0-2; 
and Ra is (a) hydrogen or (b) an organic 

group bonded via a carbon atom selected from 
substituted or unsubstituted (C₁-C₄)alkyl, 

 
substituted or unsubstituted (C₃-C₆)cycloalkyl, 

substituted or unsubstituted 
(C₂-C₄)alkenyl, substituted or unsubstituted 

(C₂-C₄)alkynyl, substituted or unsubstituted 
aryl, substituted or unsubstituted heteroaryl, 

substituted or unsubstituted 
aryl(C₁-C₆)alkyl, substituted or unsubstituted 

heterocyclyl, substituted or unsubstituted 
fused heterocyclyl, said substitution 

is selected from (C₁-C₄)alkyl, hydroxy, 
(C₁-C₄)alkoxy, phenyl, heterocyclyl, amino, 

amidino, guanidino, carboxamido, carbamoyl 
and quaternary ammonio; wherein the 

heteroaryl and heterocyclyl moieties are as 
hereinbefore described. 
(iii) or R₂ is hydroxy, -ORa, -OC(O)Ra, -OC(O)ORa, 
-OC(O)NRaRa or -OC(O)-C(NH₂)Ra wherein Ra is 

independently selected and is as hereinabove 
defined or 

 
wherein R₁₃ is a moiety selected from those 

of the formulae: 
 

wherein B⁻ is a physiologically acceptable 
anion; 
(iv) or R₂ is an organic residue bonded via a 
nitrogen atom, selected from 


(a) NO, NO₂, NO₃, NC, NCO, NHCN, and NRhRJ 
wherein Rh and RJ are independently 

selected from hydrogen; substituted or 
 

unsubstituted amino, substituted or 
unsubstituted (C₁-C₄)alkyl and 

(C₃-C₆)cycloalkyl(C₁-C₄)alkyl, aryl, 
aralkyl, heterocyclyl, 

heterocyclyl(C₁-C₄)alkyl, heteroaryl and 
heteroaryl(C₁-C₄)alkyl wherein the 

heteroatom or heteroatoms are selected 
from oxygen, nitrogen and sulfur, and a 

cyclic group wherein Rh and RJ taken 
together with the associated nitrogen is 

an unsubstituted or substituted mono- or 
bicyclic heterocyclic ring having up to 

four (4) heteroatoms in each ring independently 
selected from oxygen, 

nitrogen and sulfur wherein the 
substituents in the aforementioned substituted 

alkyl, amino and heterocyclic 
groups consist of amino, mono-, di- and 

tri(C₁-C₄)alkylamino, hydroxyl, oxo, 
carboxyl, alkoxyl, chloro, fluoro, 

bromo, nitro, -SO₂NH₂, phenyl, benzyl, 
acyloxy, alkoxylcarbonyloxy, 

cycloalkoxycarbonyloxy and carboxamido; 
(b) a hydroxylamino, hydrazinyl, and 
hydroxamic acid derivative of the 

formulae: 
-N(Rh)ORJ, -N(Rh)NRhRJ, and 

 
respectively; wherein Rh and RJ are as 

hereinabove defined; 
(c) moieties of the formulae:  
   and 

 
wherein Rh and RJ are as hereinabove 

defined; 
(d) an acylamino moiety of the formula: 
 

wherein Rh and RJ are as hereinabove 
defined; 
(e) moieties represented by the formulae: 
 

wherein Rh and RJ are as hereinabove 
defined and RP is selected from oxygen 

and sulfur; 
(f) moieties of the formula: 

 

wherein Rk represents hydrogen, 
(C₁-C₃)alkyl, (C₂-C₄)alkenyl, 

(C₂-C₄)alkynyl, heterocyclyl and 
heteroaryl wherein the heteroatom or 

heteroatoms are selected from 1-4 
oxygen, nitrogen or sulfur and the 

cyclic portion has 5 or 6 ring atoms; 
(g) moieties of the formula: 
RaS(O)n''NH- 

wherein n'' and Ra are as hereinabove 
defined; 
(h) an amino moiety containing an acyl 
residue of an amino acid or peptide represented 

by the formula: 
 

wherein Rh is as hereinabove defined; Rm 
is hydrogen or an acyl residue of an 

amino acid or peptide; and Rt is 
hydrogen, benzyl, straight or branched 

(C₁-C₄)alkyl optionally substituted with 
halo, hydroxy, amino, guanidinyl, 

carboxy, phenyl, aminocarbonyl, 
alkylthio, hydroxyphenyl or heterocyclyl; 
(i) an acyclic quaternary ammonio moiety of 
the formula: 

B⁻ -N⁺R₇R₈R₉ 
wherein B⁻ is a physiologically 

acceptable anion and R₇, R₈ and R₉ are 
the same or different and are selected 

from hydrogen, a straight or branched 
(C₁-C₄)alkyl, (C₂-C₄)alkenyl and substituted 

(C₁-C₄)alkyl, wherein the 
 

substitution is selected from hydroxy, 
(C₁-C₄)alkoxy, azido, amino, 

(C₁-C₄)alkylamino, di(C₁-C₄)alkylamino, 
guanidino, nitrile, carboxy, formimidoyl 

and phenyl: alternatively, R₇ and R₈ 
taken together are -(CH₂)₂X(CH₂)₂-, 

wherein X is (CH₂)w (w is an integer 
from 0 to 2), oxygen, sulfur, NH, NRh, 

NOH and NORh; and 
(j) a quaternized heteroaryl wherein the 
heteroatoms are selected from 1-4 

oxygen, nitrogen and sulfur atoms with 
the proviso that the heteroaryl moiety 

must contain at least one positively 
charged nitrogen atom in association 

with a physiologically acceptable anion 
wherein the quaternized heteroaryl is 

optionally substituted by Ra as 
hereinabove defined; 
(v) or R₂ is a moiety bonded via a carbon atom 
selected from the following groups: 


(a) a nitrile moiety, an acetylenic moiety 
or a moiety of the formulae: 

-C≡ C-Ra 
wherein Ra is as hereinabove defined; 
(b) a moiety selected from the following 
formulae: 
(c) a moiety selected from -CHF₂, CF₃, 
-CF₂CF₃, -CH(OCH₃)₂, -CHCl₂ or CHRhRJ; 
(F) R₃ is hydrogen; a straight or branched (C₁-C₄)-alkyl 
group; a (C₁-C₄)alkoxymethyl group; a 

straight or branched 1-(C₁-C₅)aliphatic acyloxyethyl 
or methyl group; a straight, branched or 

cyclic 1-(C₁-C₆)alkoxycarbonyloxy-ethyl or methyl 
group; a phthalidyl group; or water soluble 

cations selected from lithium, sodium, potassium, 
ammonium or tetra(C₁-C₄)alkyl ammonium and the 

pharmaceutically acceptable salts thereof. 
A compound according to Claim 1, 
wherein n is as described in Claim 1, Z is oxygen and: 


(A) Ro is -CH(OR₄)CH₃; 

   R₄ is selected from hydrogen, and moieties of the 
formulae: 

 
wherein R₆ is selected from a straight, branched 

or substituted (C₁-C₁₈)alkyl, (C₂-C₁₈)alkenyl, 
unsubstituted or substituted 

 
(C₃-C₇)monocyclo(C₁-C₁₀)alkyl, unsubstituted or 

substituted (C₅-C₁₀)bicyclo(C₁-C₁₀)alkyl, phenyl 
substituted phenyl; the substitution for the 

alkyl, monocycloalkyl and bicycloalkyl are 
selected from trifluoromethyl, pentafluoroethyl, 

amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 
hydroxy, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, 

carboxy, (C₂-C₁₀)carboalkoxy, cyano, and 
(C₁-C₁₀)carboxamido; the substitution for the 

phenyl group is selected from (C₁-C₆)alkyl, 
(C₁-C₆)mono-, di- or polyfluoroalkyl, hydroxy, 

(C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, amino, 
mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, 

carboxy, (C₂-C₁₀)carboalkoxy, cyano and 
(C₁-C₁₀)carboxamido; 
(B) R₁ is straight or branched (C₁-C₄)alkyl, straight 
or branched (C₂-C₄)alkenyl, or (CH₂)n,R; 

n' is an integer of from 1-4; R is selected from 
CF₃, C₂F₅, fluorine, chlorine, bromine, hydroxy, 

alkoxy, nitrile, azido, a quaternary ammonio 
group, amidino, formamidino, guanidino and NR'R''; 

wherein R' and R'' are independently selected from 
hydrogen, straight or branched (C₁-C₄)alkyl, and 

straight or branched (C₁-C₄)alkoxy; 
and when R' is hydrogen or straight or branched 

(C₁-C₄)alkyl, R'' may also be selected from amino, 
hydroxy, mono(C₁-C₄)alkylamino, 

di(C₁-C₄)alkylamino, acyl, benzoyl, and dihydroxybenzoyl, 
(C) R₂ is 

(i) methyl, fluorine, chlorine, bromine, iodine, 
-OCOCH₃, -OCOCF₃, -OSO₂CH₃, -OSO₂Ph, azido, 
(ii) a moiety of the formula: 
-S(O)n''Ra 

wherein n'' is an integer from 0-2; 
and Ra is hydrogen or an organic group bonded 

via a carbon atom selected from substituted 
 

or unsubstituted (C₁-C₄)alkyl, substituted or 
unsubstituted (C₃-C₆)cycloalkyl, substituted 

or unsubstituted (C₂-C₄)alkenyl, substituted 
or unsubstituted (C₂-C₄)alkynyl, substituted 

or unsubstituted phenyl, said substitution is 
selected from (C₁-C₄)alkyl, hydroxy, 

(C₁-C₄)alkoxy, phenyl, amino, amidino, 
guanidino, carboxamido, carbamoyl and 

quaternary ammonio: 
(iii) hydroxy, -ORa, -OC(O)Ra, -OC(O)ORa, 
-OC(O)NRaRa or -OC(O)-C(NH₂)Ra wherein Ra is 

independently selected and is as hereinabove 
defined or 

 
wherein R₁₃ is a moiety selected from those 

of the formulae: 
 

wherein B⁻ is a physiologically acceptable 
anion, 
(iv) or R₂ is an organic residue bonded via a 
nitrogen atom, selected from -NRhRJ, and 

moieties of the formulae:  
wherein Rh and RJ are independently selected 

from hydrogen; substituted or unsubstituted 
(C₁-C₄)alkyl (C₃-C₆)cycloalkyl(C₁-C₄)alkyl, 

substituted and unsubstituted phenyl and with 
respect to the NRhRJ moiety, Rh and RJ taken 

together with the associated nitrogen is an 
unsubstituted or substituted mono- or 

bicyclic heterocyclic ring having from 5-7 
atoms in each ring and up to four (4) 

heteroatoms in each ring independently 
selected from oxygen, nitrogen and sulfur 

wherein the substituents consist of amino, 
mono-, di- and tri(C₁-C₄)alkylamino, 

hydroxyl, oxo, carboxyl, alkoxyl, chloro, 
fluoro, bromo, nitro, -SO₂NH₂, phenyl, 

benzyl, alkoxylcarbonyl, acyloxy, 
alkoxycarbonyloxy, cycloalkoxycarbonyloxy and 

carboxamido; RP is oxygen or sulfur; Rm is 
hydrogen or an acyl residue of an amino acid 

or peptide; and Rt is hydrogen, benzyl, 
straight or branched (C₁-C₄)alkyl optionally 

 
substituted with halo, hydroxy, amino, 

guanidinyl, carboxy, phenyl, aminocarbonyl, 
alkylthio, or hydroxyphenyl, 

and R₇, R₈ and R₉ are the same or different 
and are selected from hydrogen, a straight or 

branched (C₁-C₄)alkyl, (C₂-C₄)alkenyl and 
substituted (C₁-C₄)alkyl, wherein the 

substitution is selected from hydroxy, 
(C₁-C₄)alkoxy, azido, amino, 

(C₁-C₄)alkylamino, di(C₁-C₄)alkylamino, 
guanidino, nitrile, carboxy, formimidoyl and 

phenyl: alternatively, R₇ and R₈ taken 
together are -(CH₂)₂X(CH₂)₂-, wherein X is 

(CH₂)w (w is an integer from 0 to 2), oxygen, 
sulfur, NH, NRh, NOH and NORh; 
(v) or R₂ is a moiety bonded via a carbon atom; 
selected from the following groups: 


(a) a moiety selected from a nitrile moiety, 
an acetylene moiety or a moiety of the 

formulae: 
-C≡C-Ra 

wherein Ra is as hereinabove defined; 
(b) moiety selected from those of the 
formulae: 

 
wherein Ra, Rh and RJ are as hereinabove 

defined; 
(c) a moiety selected from -CHF₂, CF₃, 
-CF₂CF₃, -CH(OCH₃)₂, CHRhRJ or -CHCl₂; 
(D) R₃ is selected from hydrogen; a straight or 
branched (C₁-C₄)alkyl group; a (C₁-C₄)alkoxymethyl 

group; a straight or branched 1-(C₁-C₅)aliphatic 
acyloxy-ethyl or methyl group; a straight, 

branched or cyclic 1-(C₁-C₆)alkoxycarbonyloxyethyl 
or methyl group; a phthalidyl group; and a 

water soluble cation selected from lithium, 
sodium, potassium, ammonium and tetra(C₁-C₄)alkyl 

ammonium, and the pharmaceutically acceptable 
salts thereof. 
A compound according to Claim 1, 
wherein n is as described in Claim 1, Z is oxygen and: 

Ro is -CH(OR₄)CH₃; 
R₄ is selected from hydrogen; and moieties of the 

formulae: 
 

R₆ is selected from a straight, branched or substituted 
(C₁-C₁₈)alkyl, (C₂-C₁₈)alkenyl, unsubstituted or substituted 

(C₃-C₇)monocyclo(C₁-C₁₀)alkyl, unsubstituted 
or substituted (C₅-C₁₀)bicyclo(C₁-C₁₀)alkyl, phenyl and 

substituted phenyl; the substitution for the alkyl, 
monocycloalkyl and bicycloalkyl are selected from 

trifluoromethyl, pentafluoroethyl, amino, 
mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, hydroxy, 

(C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, carboxy, 
(C₂-C₁₀)carboalkoxy, cyano and (C₁-C₁₀)carboxamido; the 

substitution for the phenyl group is selected from 
 

(C₁-C₆)alkyl, (C₁-C₆)mono-, di- or polyfluoroalkyl, 
hydroxy, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkoxy, amino, 

mono (C₁-C₆)alkylamino, di (C₁-C₆)alkylamino, carboxy, 
(C₂-C₁₀)carboalkoxy, cyano and (C₁-C₁₀)carboxamido; 

R₁ is selected from the group consisting of straight 
(C₁-C₃)alkyl, CH₂CF₃ and CH₂CF₂CF₃; 

R₂ is selected from the group consisting of: 

(a) methyl, fluorine, chlorine, bromine, 
iodine, -OCOCH₃, -OCOCF₃, -OSO₂CH₃, 

-OSO₂Ph, azido, 
(b) a moiety of the formula: 
-S(O)n''Ra 

wherein n'' is an integer from 0-2; 
and Ra is hydrogen, substituted or 

unsubstituted (C₁-C₄)alkyl, substituted 
or unsubstituted phenyl, wherein the 

substituent in said substituted alkyl or 
phenyl group is selected from 

(C₁-C₄)alkyl, hydroxy, (C₁-C₄)alkoxy, 
amino, amidino, guanidino, carboxamido, 

carbamoyl and quaternary ammonio; 
(c) hydroxy, -ORa, -OC(O)NRaRa or 
-OC(O)-C(NH₂)Ra wherein Ra is 

independently selected and is as 
hereinabove defined or 

 
wherein R₁₃ is a moiety selected from 

those of the formulae: 

 

wherein B⁻ is a physiologically 
acceptable anion, 
(d) moieties of the formulae: -NRhRJ, 
 

wherein Rh and RJ are independently 
selected from hydrogen; substituted or 

unsubstituted (C₁-C₄)alkyl and (C₃-C₆)-cycloalkyl(C₁-C₄)alkyl, 
phenyl or 

substituted phenyl wherein the substituents 
consist of amino, mono-, di- and 

tri(C₁-C₄)alkylamino, hydroxyl, oxo, 
carboxyl, alkoxyl, chloro, fluoro, 

bromo, nitro, -SO₂NH₂, phenyl, benzyl, 
acyloxy, alkoxylcarbonyloxy, cycloalkoxycarbonyloxy 

and carboxamido; RP is 
oxygen or sulfur; Rm is hydrog
en or an 
acyl residue of an amino acid or peptide 

and Rt is hydrogen or (C₁-C₄)alkyl, and 
R₇, R₈ and R₉ are the same or different 

and are selected from hydrogen, a 
straight or branched (C₁-C₄)alkyl, 

(C₂-C₄)alkenyl and substituted 
 

(C₁-C₄)alkyl, wherein the substitution 
is selected from hydroxy, (C₁-C₄)alkoxy, 

azido, amino, (C₁-C₄)alkylamino, 
di(C₁-C₄)alkylamino, guanidino, nitrile, 

carboxy, formimidoyl and phenyl; 
alternatively, R₇ and R₈ taken together 

are -(CH₂)₂X(CH₂)₂-, wherein X is (CH₂)w 
(w is an integer from O to 2), oxygen, 

sulfur, NH, NRh, NOH and NORh; 
(e) or R₂ is a moiety; selected from the 
following groups; 


(1) a nitrile group; 
(2) a moiety selected from those of the 
formulae: 

 
wherein Rh and RJ are as 

hereinabove defined; 
(3) a moiety selected from -CHF₂, CF₃, 
-CF₂CF₃, -CH(OCH₃)₂, CHRhRJ or 

-CHCl₂; 
 
R₃ is hydrogen; a straight or branched (C₁-C₄)alkyl 

group; a (C₁-C₄)alkoxymethyl group; a straight or 
branched 1-(C₁-C₅)aliphatic acyloxy-ethyl or methyl 

group; a straight, branched or cyclic 1-(C₁-C₆)alkoxycarbonyloxy-ethyl 
or methyl group; a phthalidyl group; 

and water soluble cations selected from lithium, 
sodium, potassium, ammonium and tetra(C₁-C₄)alkyl 

 
ammonium and the pharmaceutically acceptable salts 

thereof. 
A compound according to Claim 1, wherein n is 
as described in Claim 1, Z is oxygen and: 

Ro is -CH(OR₄)CH₃; R₄ is selected from hydrogen; 
R₁ is selected from the group consisting of straight 

(C₁-C₃)alkyl; 
R₂ is selected from the group consisting of: 


(a) methyl, fluorine, chlorine, -OCOCH₃, 
-OCOCF₃, -OSO₂CH₃, -OSO₂Ph, azido; 
(b) hydroxy, -ORa, or -OC(O)-C(NH₂)Ra 
wherein Ra is hydrogen, substituted or 

unsubstituted (C₁-C₄)alkyl, substituted 
or unsubstituted phenyl, wherein the 

substituent in said substituted alkyl or 
phenyl group is selected from 

(C₁-C₄)alkyl, hydroxy, (C₁-C₄)alkoxy, 
amino, amidino, guanidino, carboxamido, 

carbamoyl and quaternary ammonio; 
(c) moieties of the formulae: -NRhRJ, 
 

wherein Rh and RJ are independently 
selected from hydrogen; substituted or 

 
unsubstituted (C₁-C₄)alkyl and (C₃-C₆)-cycloalkyl(C₁-C₄)alkyl, 

phenyl or 
substituted phenyl wherein the substituents 

consist of amino, mono-, di- and 
tri(C₁-C₄)alkylamino, hydroxyl, oxo, 

carboxyl, alkoxyl, chloro, fluoro, 
bromo, nitro, -SO₂NH₂, phenyl, benzyl, 

acyloxy, alkoxylcarbonyloxy, cycloalkoxycarbonyloxy 
and carboxamido; RP is 

oxygen or sulfur; Rm is hydrogen or an 
acyl residue of an amino acid or peptide 

and Rt is hydrogen or (C₁-C₄)alkyl; 
(d) or R₂ is a moiety selected from the 
following groups; 


(1) a nitrile group; 
(2) a moiety selected from those of the 
formulae: 

 
wherein Rh and RJ are as 

hereinabove defined; 
(3) a moiety selected from CHRhRJ; 
 
R₃ is hydrogen; a straight or branched (C₁-C₄)alkyl 

group; a (C₁-C₄)alkoxymethyl group; a straight or 
branched 1-(C₁-C₅)aliphatic acyloxy-ethyl or methyl 

group; a straight, branched or cyclic 1-(C₁-C₆)alkoxycarbonyloxy-ethyl 
or methyl group; a phthalidyl group; 

and water soluble cations selected from lithium, 
sodium, potassium, ammonium and tetra(C₁-C₄)alkyl 

 
ammonium and the pharmaceutically acceptable salts 

thereof. 
A compound selected from those of formula IV 
and IX: 

 
wherein: 

Y is selected from chloro, bromo, iodo, methanesulfonate 
and trifluoromethanesulfonate; 

n is an integer from 0-4; 
Z is selected from oxygen, sulfur, sulfoxide and 

sulfone; 
R₂ is selected from: 


(i) methyl, hydrogen, fluorine, chlorine, 
bromine, iodine, -OCOCH₃, -OCOCF₃, 

-OSO₂CH₃, -OSO₂Ph, azido, 
(ii) a moiety of the formula: 
-S(O)n''Ra 

wherein n'' is an integer from 0-2; 
and Ra is hydrogen or an organic group 

bonded via a carbon atom selected from 
substituted or unsubstituted 

(C₁-C₄)alkyl, substituted or 
unsubstituted (C₃-C₆)cycloalkyl, 

 
substituted or unsubstituted 

(C₂-C₄)alkenyl, substituted or 
unsubstituted (C₂-C₄)alkynyl, 

substituted or unsubstituted aryl, 
substituted or unsubstituted heteroaryl, 

substituted or unsubstituted 
aryl(C₁-C₆)alkyl, substituted or unsubstituted 

heterocyclyl, any of such 
groups being optionally substituted; 

said substitution is selected from 
(C₁-C₄)alkyl, hydroxy (C₁-C₄)alkoxy, 

phenyl, heterocyclyl, amino, amidino, 
guanidino, carboxamido, carbamoyl, and 

quaternary ammonio; 
(c) or R₂ is hydroxy, -ORa, -OC(O)Ra, 

-OC(O)ORa, -OC(O)NRaRa or 
 

wherein Ra is independently selected 
and is as hereinabove defined or 

 
wherein R₁₃ is a moiety selected from 

those of the formulae: 

(iv) or R₂ is an organic residue bonded via a 
nitrogen atom, selected from 


(a) NO, NO₂, NO₃, NC, NCO, NHCN, and 
NRhRJ wherein Rh and RJ are 

independently selected from 
hydrogen; amino; substituted or 

unsubstituted amino; substituted or 
unsubstituted (C₁-C₄)alkyl and 

(C₃-C₆)cycloalkyl(C₁-C₄)alkyl, 
aryl, aralkyl, heterocyclyl, 

heterocyclyl(C₁-C₄)alkyl, 
heteroaryl and 

heteroaryl(C₁-C₄)alkyl wherein the 
heteroatom or heteroatoms are 

selected from oxygen, nitrogen and 
sulfur, and a cyclic group wherein 

Rh and RJ taken together with the 
associated nitrogen is an unsubstituted 

or substituted mono- or 
bicyclic heterocyclic ring having 

up to four (4) heteroatoms in each 
ring independently selected from 

oxygen, nitrogen and sulfur wherein 
the substituents in the afore 

mentioned substituted alkyl, amino 
and heterocyclic group consist of 

amino, mono-, di- and 
tri(C₁-C₄)alkylamino, hydroxyl, 

oxo, carboxyl, alkoxyl, chloro, 
fluoro, bromo, nitro, -SO₂NH₂, 

phenyl, benzyl, acyloxy, 
alkoxylcarbonyl, alkoxycarbonyloxy, 

cycloalkoxycarbonyloxy and 
carboxamido; 
(b) or R₂ is a hydroxylamino, 
hydrazinyl, iminyl and hydroxamic 

 
acid derivative selected from those 

of the formulae: 
-N(Rh)ORJ, -N(Rh)NRhRJ, 

 
respectively; wherein Rh and RJ are 

as hereinabove defined; 
(c) moieties of the formulae: 
 

   and 
 

wherein Rh and RJ are as 
hereinabove defined; 
(d) acylamino moieties of the formulae: 
 

wherein Rh and RJ are as 
hereinabove defined; 
(e) moieties represented by the 
formulae:  

wherein Rh and RJ are as hereinabove 
defined and RP is selected from oxygen 

and sulfur; 
(f) moieties of the formula: 
 

wherein Rk represents hydrogen, 
substituted or unsubstituted 

(C₁-C₃)alkyl*, (C₂-C₄)alkenyl*, 
(C₂-C₄)alkynyl*, heterocyclyl* and 

heteroaryl* wherein the heteroatom and 
heteroatoms are selected from 1-4 

oxygen, nitrogen or sulfur and the 
cyclic portion has 5 or 6 ring atoms; 

wherein the aforesaid groups marked with 
an asterisk are optionally substituted 

by a substituent described hereinabove 
for Rh and RJ; 
(g) moieties of the formula: 
RaS(O)n''NH- 

wherein n'' and Ra are as hereinabove 
defined; 
(h) moieties represented by the 
formulae:  

wherein Rh and RJ are as 
hereinabove defined; 
(i) an amino moiety containing an acyl 
residue of an amino acid or peptide 

represented by the formula: 
 

wherein Rh is as hereinabove 
defined; Rm is hydrogen or an acyl 

residue of an amino acid or 
peptide; and Rt is hydrogen, 

benzyl, straight or branched 
(C₁-C₆)alkyl optionally substituted 

with halo, hydroxy, amino, 
guanidinyl, carboxy, phenyl, 

aminocarbonyl, alkylthio, hydroxyphenyl 

or heterocyclyl; 
(j) an acyclic quaternary ammonio 
moiety of the formula: 

B⁻ -N⁺R₇R₈R₉ 
wherein R₇, R₈ and R₉ are the same 

or different and are selected from 
hydrogen, a straight or branched 

(C₁-C₄)alkyl, (C₂-C₄)alkenyl and 
substituted (C₁-C₄)alkyl, wherein 

the substitution is selected from 
 

hydroxy, (C₁-C₄)alkyl, wherein the 
substitution is selected from 

hydroxy, (C₁-C₄)alkoxy, azido, 
amino, (C₁-C₄)alkylamino, 

di(C₁-C₄)alkylamino, guanidino, 
nitrile, carboxy, formimidoyl and 

phenyl; alternatively, R₇ and R₈ 
taken together are -(CH₂)₂X(CH₂)₂-, 

wherein X is (CH₂)w (w is an 
integer from 0 to 2), oxygen, 

sulfur, NH, NRh, NOH and NORh and 
B⁻ is a physiologically acceptable 

anion; 
(v) or R₂ is a moiety bonded via carbon 
atom; selected from the following 

groups; 

(a) a nitrile moiety an acetylenic 
group, or a moiety of the formulae: 

-C≡C-Ra 
wherein Ra is as hereinabove 

defined; 
(b) a moiety selected from those of the 
formulae:  

wherein Ra, Rh and RJ are as hereinabove 
defined; 
(c) a moiety selected from -CHF₂, CF₃, 
-CF₂CF₃, CH(OCH₃)₂, -CHCl₂ and CHRhRJ. 
A compound selected from the group 
consisting of: 

[4R-[3(3R*,5R* and 
3S*,5S*)4alpha,5beta,6beta(R*)]]
-3-[[5-[[(Aminocarbonyl)oxy]methyl]
tetrahydro-3-furanyl]thio]
-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic 

acid 
monosodium salt; 

[4R-[3(3R*,5S* and 
3S*,5R*)4alpha,5beta,6beta(R*)]]
-3-[[5-[[(4-Fluorophenyl)sulfonyl]methyl]
tetrahydro-3-furanyl]thio]
-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic 

acid 
monosodium salt; 

[4R-[3(3R*,5S* and 3S*,5R*)4α,5β,6β(R*)]]-3-[[5-[[[(Dimethylamino)methylene]
amino]methyl]
 
tetrahydro-3-furanyl]
thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
hept-2-ene-2-carboxylic 
acid; 

[4R-[4α,5β,6β(R*)]-1-Amino-2,5-anhydro-4-S-[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
 
hept-2-en-3-yl]
-1,3-dideoxy-4-thio-D-threo-pentitol; 
[3-S-[4R-[1-(S*),4α,5β,6β(R*)]]]
-1-[(2-Amino-1-oxopropyl)amino]-2,5-anhydro-3-S-[2-carboxy-6-(1-hydroxeythyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
hept-2-en-3-yl]-1,4- 

dideoxy-3-thio-D-threo-pentitol; 
[3-S[4R-[1(S*),4alpha,5beta,6beta(R*)]]]
-1-[(2-Amino-3-methyl-1-oxopentyl)amino]-2,5-anhydro-3-S-[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
hept-2-en-3-yl]-1,4- 

dideoxy-3-thio-D-threo-pentitol; 
[3-S[4R-[1(S*,S*),4alpha,4beta,6beta(R*)]]]
-1-[(2-Amino-3-methyl-1-oxopentyl)amino]-2,5-anhydro-3-S-[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
hept-2-en-3-yl]-1,4- 

dideoxy-3-thio-D-threo-pentitol; 
[3-[4R-[4alpha,5beta,6beta(R*)]]]
-1-(Acetyloxy)ethoxy]carbonyl]
amino]-2,5-anhydro-3-S-[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]
hept-2-en-3-yl]-1,4-dideoxy-3-thio-D- 

threo-pentitol 
 

Monosodium Salt; 
[4R-[3(3R*,5R*, and 3S*,5S*)4α,5β,6β(R*)]]
-6-(1-Hydroxyethyl)-4-methyl-7-oxo-3-[[tetrahydro-5- 
(hydroxymethyl)-3-furanyl]
thio]-1-azabicyclo[3.2.0]
hept-2-ene-2-carboxylic 
acid (4-nitrophenyl)methyl 

ester. 
A method of treating bacterial infections 
in mammals which comprises administering an 

effective antibacterial amount of a compound according 
to Claim 1. 
A pharmaceutical composition of matter 
comprising a coumpound according to Claim 1 in 

association with a pharmaceutically acceptable carrier. 
A process for producing a carbapenem 
compound of the formula I: 

 
wherein R₀, R₁, R₂, R₃, Z and n are as described in 

claim 1 which comprises: 

(a) contacting a compound of the formula III: 

 

wherein R₁₅ is a carboxyl protecting group with a 
thiol compound of the formula IV: 


(b) and removing said protecting group and recovering 
the compounds of Formula I. 
A process for producing a carbapenem 
compound of the formula I: 

 
wherein R₀, R₁, R₂, R₃, Z and n are as described in 

claim 1 which comprises: 

(a) reacting a 3-bromo-2-ketoester compound of formula 
V: 


 
wherein R₁₅ is a carboxyl protecting group and TBS 

is t-butyldimethylsilyl with a thiol compound of 
the formula IV: 

 
to obtain an azetidinone compound of the formula 

VI: 

(b) hydrolyzing the TBS protecting group to obtain a 
compound of the formula VII: 


(c) reacting the compound of formula VII with a 
suitable acid to obtain a compound of the formula 

II: 
 

and 
(d) removing the carboxyl protecting group R₁₅ to 
obtain the compounds of formula I. 
A process for producing a compound of 
the formula I: 

 
wherein R₀, R₁, R₂, R₃, Z and n are as defined in claim 

1 which comprises: 

(a) reacting a silver thiolate compound of formula 
VIII 


 
wherein R₁₅ is a carboxyl protecting group with a 

substituted heterocycle compound of formula IX: 
 

wherein Y is selected from chloro, bromo, iodo, 
methanesulfonate and trifluoromethanesulfonate; to 

obtain a compound of the formula II: 

(b) and removing the carboxyl protecting group R₁₅ to 
obtain a compound of formula I. 
</CLAIMS>
</TEXT>
</DOC>
